SAN FRANCISCO, CA, May 16, 2018 – Practice Fusion, Inc., an Allscripts company and the largest connected digital health platform in the United States, announced today that it will present new real-world evidence (RWE) that includes the reclassification of hypertension for patients based on the newly revised guidelines from the American College of Cardiology (ACC) and the American Heart Association (AHA). This study will be presented at the 23rd annual meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), which will be held in Baltimore during May 19-23, 2018. This is Practice Fusion’s second in a series of poster presentations at this industry-leading conference. Through participation in conferences like ISPOR, Practice Fusion continues to be an innovator in offering RWE data solutions, while also helping Allscripts expand its suite of forward-looking, research-focused solutions and services for life sciences and healthcare organizations.
At the ISPOR conference, researchers from Practice Fusion’s Life Sciences Team will discuss the benefits of timely real-world data and present the scientific poster to those in attendance. Researchers leveraged real-world data from Practice Fusion’s nationally representative and statistically de-identified clinical database, now consisting of more than 50 million de-identified clinical records in the United States, to perform this important study.
Evaluating the Effect of the Change in ACC/AHA Blood Pressure Guidelines on the Prevalence of Diagnosed Hypertension
This retrospective study analyzed the change in estimated prevalence of hypertension among the ambulatory care patient population following the recent revision of the guidelines for managing and treating hypertension by the ACC and the AHA in 2017. The study found that the application of the new hypertension classification guidelines is estimated to result in about two thirds of patients, who are currently categorized as prehypertensive (using the 2003 guidelines), being reclassified as having Stage 1 hypertension (using the revised 2017 guidelines). This could further result in a substantial increase in the number of people being monitored for hypertension and beginning to use anti-hypertensive therapy, including non-pharmacologic activities and medication treatments.
Answering valuable research questions with the largest connected digital health platform in the U.S.
“Among many other benefits, timely data from the Practice Fusion de-identified clinical database allows researchers to evaluate initiation of new products shortly after introduction for deep clinical insights on real-world effectiveness.” said Lee Kallenbach, PhD, MPH, Director of Research at Practice Fusion.
About Practice Fusion
Practice Fusion, an Allscripts company, is the #1 cloud-based ambulatory EHR platform in the U.S.,1 supporting 30,000 medical practices in delivering better care to over 5 million patients a month. With a best-in-class satisfaction rate,2 Practice Fusion is committed to delivering intuitive and easy-to-use health IT solutions to small, independent medical practices.
Practice Fusion also offers connectivity solutions and services through its platform that can help make healthcare better for everyone—including clinical labs, pharmacies, imaging centers, health systems and other healthcare ecosystem stakeholders. These connected partners utilize the Practice Fusion platform to help coordinate care, and to help develop innovative programs to improve healthcare outcomes, reduce costs and enhance the patient experience.
Learn more about Industry-leading Real-World Evidence Solutions
Contact Dan Pucci, Vice President of Life Sciences